colistimethate sodium (TQD3524)
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 10, 2026
TQD3524-I-02: To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects
(clinicaltrials.gov)
- P1 | N=48 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025
Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Renal Disease
July 26, 2024
TQD3524-I-02: To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1 trial • Infectious Disease • Renal Disease
1 to 2
Of
2
Go to page
1